Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours

August 31, 2021 updated by: Amina Fouad Farag

Gold Nanoparticles as Novel Biomarkers for Cancer Stem Cells in Salivary Gland Tumors: A Diagnostic and Prognostic Accuracy Study

Nano-based diagnostic tool can provide promising highly sensitive, specific biomarker for early detection and treatment of salivary gland tumours compared to non-conjugated biomarkers and in turn improves patient prognosis and outcome.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Cancer stem cells form a small subset of highly tumorigenic cells within the bulk of the tumours which mainly responsible for initiation, invasion, rapid growth, metastasis and therapeutic resistance in different types of human cancers. Nowadays, nanotechnology has increasing attention in multi-disciplinary research fields. Conjugated gold nanoparticles are widely used as biomarkers and bio-delivery vehicles in the medicine as well as early and advanced cancer detection and treatment. The current work aimed to introduce a novel diagnostic and prognostic approach in early detection of cancer stem cells in salivary gland tumours using gold nanoparticles conjugated to CD24 (CD24-Gold Nanocomposite).

Study Type

Observational

Enrollment (Actual)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Giza, Egypt, 12511
        • Faculty of Dentistry, October 6 University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients presented to Oral and Maxillofacial Surgery Department, Faculty of Dentistry and Output Clinics of General Surgery Department, Faculty of Medicine, October 6 University, Giza, Egypt.

Description

Inclusion Criteria:

  • Benign PA of major and minor salivary glands (PA group),
  • CXPA of major and minor salivary glands (CXPA group).
  • Border of excision biopsy of mucocele in the lip mucosa of healthy individuals used as normal controls (Control group).
  • Surgical excision of tumors with no preoperative chemotherapy or radiotherapy. For parotid tumours partial or total parotidectomy, Surgery was performed with or without facial nerve preservation and the later was carried out commonly when the nerve was involved by tumour. For tumours in the other glands, complete surgical excision with the involved gland and the suspicious adjacent structures was performed.

Exclusion Criteria:

  • All epithelial origin salivary gland tumours other than PA and CXPA.
  • All mesenchymal origin salivary gland tumours.
  • All inflammatory and cystic lesions of salivary glands.
  • Metastasis in salivary glands.
  • Patients received preoperative chemotherapy or radiotherapy.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
CXPA group
carcinoma ex pleomorphic adenoma of major and minor salivary glands.
Diagnostic test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
Other Names:
  • CD24-AuNC expression using Real-time qPCR
Diagnostic test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Other Names:
  • CD24 expression using Real-time qPCR
PA group
Benign pleomorphic adenoma of major and minor salivary glands.
Diagnostic test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
Other Names:
  • CD24-AuNC expression using Real-time qPCR
Diagnostic test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Other Names:
  • CD24 expression using Real-time qPCR
Control group
normal controls obtained from border of excision biopsy of mucocele in the lip mucosa of healthy individuals.
Diagnostic test: CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction
new strategy where gold nanoparticles synthetized and added to CD24 primer forming CD24-Gold Nanocomposite to be used for detection of cancer stem cells
Other Names:
  • CD24-AuNC expression using Real-time qPCR
Diagnostic test: non-conjugated CD24 expression using Real-time quantitative polymerase chain reaction
conventional strategy using non-conjugated CD24 expression to used for detection of cancer stem cells
Other Names:
  • CD24 expression using Real-time qPCR

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic potential of CD24-AuNC (index test) compared to non-conjugated CD24 (reference test) in determination of salivary gland tumours
Time Frame: Done immediately following completion of assessment for eligibility of enrolment in the present study (enrolment took about 6 months) and confirmation of definite diagnosis
we tested the differential expression of CD24-AuNC and non-conjugated CD24 biomarkers in all studied groups in order to identify the most sensitive and specific diagnostic biomarker to be used in detecting salivary gland tumours,
Done immediately following completion of assessment for eligibility of enrolment in the present study (enrolment took about 6 months) and confirmation of definite diagnosis

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinicopathological characteristics of the patients and their association with CD24-AuNC (Index test) and non-conjugated CD24 (Reference test) expressions
Time Frame: Done immediately following completion of assessment for eligibility of enrolment in the present study (enrolment took about 6 months) and confirmation of definite diagnosis
We investigated the relationship between both biomarkers' expression and clinicopathological characteristics of PA and CXPA patients such as age, gender, tumor site, tumor size (maximum diameter in mm), histopathological subtype, encapsulation, degree of invasion, facial nerve involvement and lymph node (LN) metastasis that may have direct relation with the tumor prognosis
Done immediately following completion of assessment for eligibility of enrolment in the present study (enrolment took about 6 months) and confirmation of definite diagnosis
Prognostic significance of CD24-AuNC (index test) compared to non-conjugated CD24 (reference test) in assessing disease progression and/or patient survival
Time Frame: At regular intervals every 3 months for 24-months (follow-up period)
we assessed the disease progression and/or patient survival and examined its association with biomarkers expression
At regular intervals every 3 months for 24-months (follow-up period)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Amina Fouad Farag

Investigators

  • Principal Investigator: Amina F Farag, PhD, Faculty of Dentistry, October 6 University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 6, 2018

Primary Completion (Actual)

February 3, 2019

Study Completion (Actual)

February 3, 2021

Study Registration Dates

First Submitted

May 25, 2021

First Submitted That Met QC Criteria

May 27, 2021

First Posted (Actual)

May 28, 2021

Study Record Updates

Last Update Posted (Actual)

September 1, 2021

Last Update Submitted That Met QC Criteria

August 31, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RECO6U/5-2018

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Carcinoma Ex Pleomorphic Adenoma of Salivary Glands

Clinical Trials on CD24-Gold Nanocomposite expression using Real-time quantitative polymerase chain reaction

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe